Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Lung Cancer: Targets and Therapy

Volumn 3, Issue , 2012, Pages 1-14

  Zienolddiny, Shanbeh ^a   Skaug, Vidar ^a  

^a NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

Author keywords

Lung cancer; Non small cell lung cancer; Polymorphism; Single nucleotide polymorphism; Susceptibility

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALKYLATING AGENT; CARCINOGEN; CISPLATIN; DOPAMINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NAVELBINE; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEMETREXED; PLATINUM COMPLEX; PROTEIN P53;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BIOTRANSFORMATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; DNA REPAIR; GENE MUTATION; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PHARMACOGENETICS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKE;

EID: 84864423785     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: None     Document Type: Review

References (181)

1. International Agency for Research on Cancer. GLOBOCAN 2008: The GLOBOCAN Project [website on the Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/. Accessed December 19, 2011.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol. 2008;13(2):102-111.
5. Parkin DM, Ferlay J, Curado MP, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010;127(12):2918-2927.
6. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12(4):399-408.
7. Christiani DC. The environment and the lung: detection, prevention, and mechanism of disease. Proc Am Thorac Soc. 2010;7(2):146-148.
8. Sugimura H, Tao H, Suzuki M, et al. Genetic susceptibility to lung cancer. Front Biosci (Schol Ed). 2011;3:1463-1477.
9. Peters S, Kromhout H, Olsson AC, et al. Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax. August 19, 2011. [Epub ahead of print.]
10. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278-281.
11. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat. 2011;32(5):526-531.
12. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on cytochrome P450. Toxicol Sci. 2011;120(1):1-13.
13. Zhong Y, Carmella SG, Upadhyaya P, et al. Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides. Chem Res Toxicol. 2011;24(2):246-252.
14. Pratt MM, John K, Maclean AB, et al. Polycyclic aromatic hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues. Int J Environ Res Public Health. 2011;8(7):2675-2691.
15. Kim JS, Park JY, Chung WY, et al. Polymorphisms in genes coding for enzymes metabolizing smoking-derived substances and the risk of periodontitis. J Clin Periodontol. 2004;31(11):959-964.
16. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 2000;92(10):803-811.
17. Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer. 2006;119(4):741-744.
18. Gasperino J. Gender is a risk factor for lung cancer. Med Hypotheses. 2011;76(3):328-331.
19. Uppstad H, Osnes GH, Cole KJ, et al. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer. 2011;71(3):264-270.
20. Piipari R, Savela K, Nurminen T, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer. 2000;86(5):610-616.
21. Smith TJ, Guo Z, Guengerich FP, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis. 1996;17(4):809-813.
22. Bloom J, Hinrichs AL, Wang JC, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European- Americans. Pharmacogenet Genomics. 2011;21(7):403-416.
23. Bartsch H, Rojas M, Alexandrov K, et al. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics. 1995;5 Spec No:S84-S90.
24. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000;9(1):3-28.
25. Chen Z, Li Z, Niu X, et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis. 2011;26(3):437-446.
26. Zienolddiny S, Skaug V, Landvik NE, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis. 2009;30(8):1368-1371.
27. Xun WW, Brennan P, Tjonneland A, et al. Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). Mutagenesis. 2011;26(5):657-666.
28. Chen B, Qiu LX, Li Y, et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501subjects. Lung Cancer. 2010;70(3):247-252.
29. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 2000;60(13):3440-3444.
30. Helmig S, Seelinger JU, Philipp-Gehlhaar M, Dohrel J, Schneider J. Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism. Eur J Epidemiol. 2010;25(12):867-873.
31. Helmig S, Seelinger JU, Dohrel J, Schneider J. RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554 Lys polymorphism. Mol Genet Metab. 2011;104(1-2):180-184.
32. Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol Cancer Ther. 2010;9(12):3315-3321.
33. Ada AO, Kunak C, Hancer F, et al. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma. 2010;57(6):512-521.
34. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 2009;1790(11): 1555-1568.
35. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9(6):520-531.
36. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29(6):1164-1169.
37. McKay JD, Hashibe M, Hung RJ, et al. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. Cancer Epidemiol Biomarkers Prev. 2008;17(1):141-147.
38. Boccia S, Boffetta P, Brennan P, et al. Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett. 2009;273(1): 55-61.
39. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. J Hum Genet. 2008;53(4):340-348.
40. Tilak AR, Kumar S, Jain M, et al. Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility. Cancer Invest. 2011;29(6):411-418.
41. Lee J, Dahl M, Nordestgaard BG. Genetically lowered microsomal epoxide hydrolase activity and tobacco-related cancer in 47,000 individuals. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1673-1682.
42. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology. 2006;17(1):89-99.
43. Ataian Y, Krebs JE. Five repair pathways in one context: chromatin modification during DNA repair. Biochem Cell Biol. 2006;84(4): 490-504.
44. Mannuss A, Trapp O, Puchta H. Gene regulation in response to DNA damage. Biochim Biophys Acta. August 16, 2011. [Epub ahead of print.]
45. Shen H, Spitz MR, Qiao Y, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer. 2003;107(1):84-88.
46. Rouillon C, White MF. The evolution and mechanisms of nucleotide excision repair proteins. Res Microbiol. 2011;162(1):19-26.
47. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4(2):59-71.
48. Kiyohara C, Takayama K, Nakanishi Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis. J Nucleic Acids. 2010;2010:701760.
49. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat Res. 2011;711(1-2):61-72.
50. Hiom K. Coping with DNA double strand breaks. DNA Repair (Amst). 2010;9(12):1256-1263.
51. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711(1-2):193-201.
52. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66(6):981-993.
53. Klungland A, Bjelland S. Oxidative damage to purines in DNA: role of mammalian Ogg1. DNA Repair (Amst). 2007;6(4):481-488.
54. Svilar D, Goellner EM, Almeida KH, Sobol RW. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal. 2011;14(12):2491-2507.
55. Vens C, Begg AC. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol. 2010;20(4):241-249.
56. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine- DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 2011;1816(2):179-190.
57. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery. 2010;67(6): 1681-1691.
58. Vineis P, Manuguerra M, Kavvoura FK, et al. A field synopsis on lowpenetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst. 2009;101(1):24-36.
59. Ricceri F, Matullo G, Vineis P. Is there evidence of involvement of DNA repair polymorphisms in human cancer? Mutat Res. August 12, 2011. [Epub ahead of print.]
60. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-991.
61. Yu H, Zhao H, Wang LE, et al. An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. DNA Repair (Amst). 2011;10(4):398-407.
62. Christiani DC. ERCC2/XPD polymorphisms and lung cancer risk. J Thorac Oncol. 2011;6(1):233-235.
63. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005;162(10):925-942.
64. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27(3):560-567.
65. Park SY, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer. 2010;9:222.
66. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749-758.
67. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66(10):5104-5110.
68. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:583929.
69. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005;5(1):3-8.
70. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002;21(17):2750-2761.
71. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26(9): 1317-1323.
72. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602.
73. Lind H, Ekstrom PO, Ryberg D, et al. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(10):2077-2081.
74. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25(25): 3489-3500.
75. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer. 2006;119(3):718-721.
76. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 2006;118(5): 1275-1278.
77. Pine SR, Mechanic LE, Bowman ED, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1559-1561.
78. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28(11):2262-2267.
79. Wo X, Han D, Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. J Genet Genomics. 2011;38(8):341-350.
80. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010;2(5):a001032.
81. Dong J, Ren B, Hu Z, et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog. 2011;50(6):433-438.
82. Vikhanskaya F, Siddique MM, Kei LM, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res. 2005;11(12):4348-4356.
83. Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet. 2006;169(2):121-127.
84. Zienolddiny S, Martinsen K, Skuag V, Ekstrom PO, Haugen A. The caspase-8 insertion/deletion polymorphism and risk of non-small cell lung cancer. Am J Biomed Sci. 2010;2:121-128.
85. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431(7007):405-406.
86. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
87. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One. 2011;6(3):e17479.
88. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1112-1122.
89. Bi N, Yang M, Zhang L, et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2383-2390.
90. Wu YC, Su LJ, Wang HW, et al. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1167-1174.
91. Kim SJ, Rabbani ZN, Dong F, et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized nonsmall cell lung cancer. Med Oncol. 2010;27(1):91-97.
92. Li F, Liu Y, Chen H, et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res. 2011;30:27.
93. Elrod HA, Yue P, Khuri FR, Sun SY. Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. Mol Cancer Ther. 2009;8(9):2575-2585.
94. Fontaine E, McShane J, Page R, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg. 2010;38(1):21-26.
95. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010;9(7): 1931-1944.
96. Ju R, Wu D, Guo L, et al. Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. Eur J Cancer. July 16, 2011. [Epub ahead of print.]
97. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25(2): 229-235.
98. Engels EA, Wu X, Gu J, et al. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67(13):6520-6527.
99. Lind H, Zienolddiny S, Ryberg D, et al. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer. 2005;50(3):285-290.
100. Zienolddiny S, Ryberg D, Maggini V, et al. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004;109(3):353-356.
101. Landvik NE, Hart K, Skaug V, et al. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis. 2009;30(7):1186-1192.
102. Lind H, Haugen A, Zienolddiny S. Differential binding of proteins to the IL1B -31 T/C polymorphism in lung epithelial cells. Cytokine. 2007;38(1):43-48.
103. Hart K, Haugen A, Zienolddiny S. Allele-specific induction of IL1B-31T/C promoter polymorphism by lung carcinogens. Mutat Res. 2008;656(1-2):14-18.
104. van den Borst B, Souren NY, Gielen M, et al. Association between the IL6-174G/C SNP and maximally attained lung function. Thorax. 2011;66(2):179-180.
105. He JQ, Foreman MG, Shumansky K, et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax. 2009;64(8):698-704.
106. Gao LB, Pan XM, Jia J, et al. IL-8 -251 A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer. 2010;46(8): 1333-1343.
107. Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet. 2001;69(2):413-419.
108. Mekinian A, Tamouza R, Pavy S, et al. Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw. 2011;22(2):88-102.
109. Wei S, Niu J, Zhao H, et al. Association of a novel functional promoter variant (rs2075533 C. T) in the apoptosis gene TNFSF8 with risk of lung cancer - a finding from Texas lung cancer genome-wide association study. Carcinogenesis. 2011;32(4):507-515.
110. Hart K, Landvik NE, Lind H, et al. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71(2): 123-129.
111. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008;639(1-2):89-100.
112. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633-637.
113. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404-1406.
114. Tournier JM, Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. Curr Opin Oncol. 2011;23(1): 83-87.
115. Sarginson JE, Killen JD, Lazzeroni LC, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3): 275-284.
116. Kaur-Knudsen D, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. J Clin Oncol. 2011;29(21): 2875-2882.
117. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun. 2001;280(4):1148-1154.
118. Senogles SE. D2 s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol. 2003;209(1-2):61-69.
119. Senogles SE. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs. 2007;18(7):801-807.
120. Campa D, Zienolddiny S, Lind H, et al. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. Lung Cancer. 2007;56(1):17-23.
121. Howlader N, Ries LA, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584-1598.
122. Brooks DR, Klint A, Dickman PW, Stahle E, Lambe M. Temporal trends in non-small cell lung cancer survival in Sweden. Br J Cancer. 2007;96(3):519-522.
123. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773-783.
124. Storm HH, Engholm G, Hakulinen T, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49(5):532-544.
125. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010;68(3): 398-402.
126. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792-801.
127. Leon-Atance P, Moreno-Mata N, Gonzalez-Aragoneses F, et al. Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. Arch Bronconeumol. 2011;47(9):441-446.
128. Serrano-Olvera A, Gerson R. Age associated survival rate in non small cell lung cancer. Gac Med Mex. 2009;145(1):27-35. Spanish.
129. Veen EJ, Janssen-Heijnen ML, Ritchie ED, et al. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome. Interact Cardiovasc Thorac Surg. 2009;9(2):260-264.
130. Palma DA, Tyldesley S, Sheehan F, et al. Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment? J Thorac Oncol. 2010;5(6):818-824.
131. Sigel K, Bonomi M, Packer S, Wisnivesky J. Effect of age on survival of clinical stage I non-small-cell lung cancer. Ann Surg Oncol. 2009;16(7):1912-1917.
132. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-215.
133. Ringer G, Smith JM, Engel AM, Hendy MP, Lang J. Influence of sex on lung cancer histology, stage, and survival in a midwestern United States tumor registry. Clin Lung Cancer. 2005;7(3):180-182.
134. Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in survival in non-small cell lung cancer patients1974-1998. Acta Oncol. 2004;43(1):57-64.
135. Jubelirer SJ, Varela NL, Welch CA, Emmett MK. Does sex make a difference in survival of patients undergoing resection for early stage nonsmall cell lung cancer (NSCLC)? W V Med J. 2009;105(4):18-22.
136. Neal DE. PSA testing for prostate cancer improves survival - but can we do better? Lancet Oncol. 2010;11(8):702-703.
137. Horgan AM, Yang B, Azad AK, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol. 2011;6(2):296-304.
138. Ada AO, Suzen SH, Iscan M. Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population. Toxicol Lett. 2004;151(1):311-315.
139. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996;56(16):3725-3730.
140. Jin Y, Xu H, Zhang C, et al. Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China. BMC Cancer. 2010;10:422.
141. Nie Q, Yang XN, An SJ, et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism. Eur J Cancer. 2011;47(13):1962-1970.
142. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. Acta Oncol. 2007;46(3):361-366.
143. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315-321.
144. Ren S, Zhou S, Wu F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer. June 13, 2011. [Epub ahead of print.]
145. Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23(4):489-498.
146. Okuda K, Sasaki H, Hikosaka Y, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res. 2011;168(2):206-212.
147. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair crosscomplementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010;67(1):101-107.
148. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006;24(26):4333-4339.
149. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118-123.
150. Yu DK, Zhang XM, Liu J, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14(9):2878-2886.
151. Han JY, Yoon KA, Park JH, et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011;117(14):3201-3208.
152. Nogueira A, Catarino R, Coelho A, et al. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother Pharmacol. 2010;66(3):501-506.
153. Jaremko M, Justenhoven C, Schroth W, et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracilbased chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics. 2007;17(7):529-538.
154. Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst. 2003;95(13):961-970.
155. Boldrini L, Gisfredi S, Ursino S, et al. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol Rep. 2008;19(3):771-773.
156. Chien WC, Wong RH, Cheng YW, Chen CY, Lee H. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol. 2010;17(4):1194-1202.
157. Chua HW, Ng D, Choo S, et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer. 2010;10:88.
158. Liu L, Wu C, Wang Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793-1800.
159. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21(WAF1/CIP1) polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000;91(1):9-15.
160. Andjelkovic T, Bankovic J, Stojsic J, et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res. 2011;157(1):19-28.
161. Landi L, Cappuzzo F. Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol. 2011;8(10): 571-573.
162. Dong J, Dai JC, Shu YQ, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis. 2010;31(6):1080-1086.
163. Sasaki H, Okuda K, Takada M, et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J Cancer Res Clin Oncol. 2008;134(12):1371-1376.
164. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010;9(3):581-593.
165. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008;8(2):129-138.
166. Minamiya Y, Miura M, Hinai Y, et al. The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2010;31(6):673-679.
167. Pankratz VS, Sun Z, Aakre J, et al. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1488-1495.
168. Pine SR, Mechanic LE, Ambs S, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst. 2007;99(18):1401-1409.
169. Hildebrandt MA, Komaki R, Liao Z, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010;5(8):e12402.
170. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31(1):37-49.
171. Vinci S, Gelmini S, Pratesi N, et al. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med. September 9, 2011. [Epub ahead of print.]
172. Navarro A, Diaz T, Gallardo E, et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol. 2010;103(5):411-415.
173. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17(7):1875-1882.
174. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating microRNA expression prof iles in early stage non-small cell lung cancer. Int J Cancer. May 4, 2011. [Epub ahead of print.]
175. Valachis A, Mauri D, Neophytou C, et al. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not? Int J Med Sci. 2011;8(6):492-500.
176. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;5(3):173-234.
177. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008;123(1):1-7.
178. He Y, Hoskins JM, Mcleod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med. 2011;17(5):244-251.
179. Yang P, Li Y, Jiang R, et al. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(1):240-244.
180. Huang YT, Heist RS, Chirieac LR, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27(16):2660-2667.
181. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. J Thorac Oncol. 2011;6(9):1496-1504.